Sanyue Traditional Chinese Medicine

Sanyue Biotech is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the modernization of Traditional Chinese Medicine (TCM). The company leverages a proprietary R&D platform to transform traditional herbal formulas into standardized, evidence-based innovative drugs. Its lead candidate, SY-001, is currently being evaluated in Phase 2 clinical trials for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Sanyue aims to address unmet medical needs in respiratory and inflammatory diseases by combining ancient medical knowledge with modern pharmacological techniques. The company is supported by leading venture capital firms such as ZhenFund and Matrix Partners China.